display
Tübingen (dpa / lsw) - The Tübingen biotech company Curevac has been critical of the initiative that companies should temporarily lose patent protection on corona vaccines.
Curevac supports measures to facilitate global access to vaccines in the current coronavirus pandemic, a company spokesman said on Thursday.
"However, we do not see patents as the decisive criterion in the provision of the largest possible quantities of vaccine and therefore do not anticipate any effects on Curevac," said the spokesman.
Rather, the general pressure on the supply chains is seen as the greatest challenge.
This results from the high demand for raw materials and equipment at the same time and in large quantities.
The spokesman added that no vaccine company had sought patents in the context of the pandemic.
International cooperation is seen as the key in the fight against Covid-19.
display
Most recently, the US government proposed that pharmaceutical companies temporarily lose patent protection for their corona vaccines.
Manufacturers around the world could then produce the vaccines without paying royalties to the companies that developed the agents.
The shares of Curevac and the corona vaccine developer Biontech from Mainz had collapsed as a result of statements from the USA.
© dpa-infocom, dpa: 210506-99-496138 / 2